Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Jaehnig EJ, Fernandez-Martinez A, Vashist TD, et al. Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell reports. Medicine. 2025:102154. doi:10.1016/j.xcrm.2025.102154 Read more